Rafivirumab  (Synonyms: CR57)

Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails^[1][2][3].

Rafivirumab 显示出对一系列 RABV 分离株的中和作用^[2]。
Rafivirumab 与 RABV 糖蛋白的抗原位点 I 结合^[3]。
Rafivirumab 完全中和野生型 ERA₄₃₉ 和 N336D R346K，EC₅₀ 范围在 3 到 5 pg/mL 之间^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Rafivirumab (3-12 μg/kg，肌肉注射) 与 CR4098 一起提高了感染蝙蝠狂犬病病毒的叙利亚仓鼠的存活率^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

944548-37-2

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35(7):2131-45.  [Content Brief]

  [2]. Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3):48.  [Content Brief]

  [3]. Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12(1):9403.  [Content Brief]